Tildacerfont for Adrenocortical Hyperfunction
Study Summary
This trial looks at whether the drug Tildacerfont is safe for children with Congenital Adrenal Hyperplasia.
- Adrenocortical Hyperfunction
- Congenital adrenal hyperplasia
- 21-OHD
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 14 days
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Cohort 1: Age 11-17 Treatment with Tildacerfont
1 of 3
Cohort 3: Age 6-10 Treatment with Tildacerfont
1 of 3
Cohort 2: Age 11-17 Treatment with Tildacerfont
1 of 3
Experimental Treatment
20 Total Participants · 3 Treatment Groups
Primary Treatment: Tildacerfont · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 18 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 31st, 2021
Last Reviewed: November 25th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.